{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:29:21Z","timestamp":1786786161843,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00428-025-04253-9","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T01:59:53Z","timestamp":1756951193000},"page":"503-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the metastatic potential of isolated tumour cells and clusters-cords patterns of ISUP Grade 5 acinar adenocarcinoma of the prostate: a comprehensive morphological analysis"],"prefix":"10.1007","volume":"489","author":[{"given":"Marina","family":"Valeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Cieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Pittarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Belsito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bressan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cimadamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia M.","family":"Elefante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Fasulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lughezzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2 M.","family":"Buffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Hurle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi M.","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6161-6138","authenticated-orcid":false,"given":"Piergiuseppe","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"2","key":"4253_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86(2):164\u2013182","journal-title":"Eur Urol"},{"issue":"4","key":"4253_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1586\/14737140.2016.1160780","volume":"16","author":"R Montironi","year":"2016","unstructured":"Montironi R, Santoni M, Mazzucchelli R, Burattini L, Berardi R, Galosi AB et al (2016) Prostate cancer: from Gleason scoring to prognostic grade grouping. Expert Rev Anticancer Ther 16(4):433\u2013440. https:\/\/doi.org\/10.1586\/14737140.2016.1160780","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"4253_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/MOU.0000000000000320","volume":"26","author":"C Magi-Galluzzi","year":"2016","unstructured":"Magi-Galluzzi C, Montironi R, Epstein JI (2016) Contemporary gleason grading and novel grade groups in clinical practice. Curr Opin Urol 26(5):488\u2013492","journal-title":"Curr Opin Urol"},{"key":"4253_CR4","first-page":"125","volume":"50","author":"D Gleason","year":"1966","unstructured":"Gleason D (1966) Classification of prostatic carcinomas. Cancer Chemother Reports 50:125\u2013128","journal-title":"Cancer Chemother Rep"},{"issue":"1","key":"4253_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pathol.2020.09.016","volume":"53","author":"C Atallah","year":"2021","unstructured":"Atallah C, Toi A, van der Kwast TH (2021) Gleason grade 5 prostate cancer: sub-patterns and prognosis. Pathology 53(1):3\u201311","journal-title":"Pathology"},{"issue":"12","key":"4253_CR6","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1097\/PAS.0000000000001550","volume":"44","author":"JK Nguyen","year":"2020","unstructured":"Nguyen JK, Chen YY, Magi-Galluzzi C, Mckenney JK (2020) Clinicopathologic study of Gleason pattern 5 prostatic adenocarcinoma with \u201csingle-cell\u201d growth reveals 2 distinct types, one with \u201cplasmacytoid\u201d features. Am J Surg Pathol 44(12):1635\u20131642","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"4253_CR7","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","volume":"29","author":"JI Epstein","year":"2005","unstructured":"Epstein JI, Allsbrook WC, Amin MB, Egevad LL, Bastacky S, L\u00f3pez Beltr\u00e1n A et al (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228\u20131242","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"4253_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244\u2013252","journal-title":"Am J Surg Pathol"},{"key":"4253_CR9","doi-asserted-by":"crossref","unstructured":"Iczkowski KA, Van Leenders GJLH, Van Der Kwast TH (2021) The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 45(7):1005\u20137","DOI":"10.1097\/PAS.0000000000001678"},{"issue":"4","key":"4253_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5858\/arpa.2020-0015-RA","volume":"145","author":"JI Epstein","year":"2021","unstructured":"Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE et al (2021) The 2019 genitourinary pathology society (GUPS) white paper on contemporary grading of prostate cancer. Arch Pathol Lab Med 145(4):461\u2013493","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"4253_CR11","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/PAS.0b013e3182495dee","volume":"36","author":"S Gottipati","year":"2012","unstructured":"Gottipati S, Warncke J, Vollmer R, Humphrey PA (2012) Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue. Am J Surg Pathol 36(6):900\u2013907","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"4253_CR12","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1111\/j.1464-410X.2012.11371.x","volume":"110","author":"HJ Chalfin","year":"2012","unstructured":"Chalfin HJ, Dinizo M, Trock BJ, Feng Z, Partin AW, Walsh PC et al (2012) Impact of surgical margin status on prostate-cancer-specific mortality. BJU Int. 110(11):1684\u20139.\u00a0https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11371.x","journal-title":"BJU Int."},{"issue":"1","key":"4253_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.euo.2018.03.013","volume":"1","author":"R Montironi","year":"2018","unstructured":"Montironi R, Zhou M, Magi-Galluzzi C, Epstein JI (2018) Features and prognostic significance of intraductal carcinoma of the prostate. Eur Urol Oncol 1(1):21\u201328. https:\/\/doi.org\/10.1016\/j.euo.2018.03.013","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"4253_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/cncr.22034","volume":"107","author":"GP Swanson","year":"2006","unstructured":"Swanson GP, Thompson IM, Basler J (2006) Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer 107(3):439\u2013450","journal-title":"Cancer"},{"issue":"9","key":"4253_CR15","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1586\/era.11.104","volume":"11","author":"J Adams","year":"2011","unstructured":"Adams J, Cheng L (2011) Lymph node-positive prostate cancer: current issues, emerging technology and impact on clinical outcome. Expert Rev Anticancer Ther 11(9):1457\u20131469","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"4253_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-02577-4","volume":"7","author":"C Luchini","year":"2017","unstructured":"Luchini C, Fleischmann A, Boormans JL, Fassan M, Nottegar A, Lucato P et al (2017) Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis. Sci Rep 7(1):1\u20137","journal-title":"Sci Rep"},{"issue":"41","key":"4253_CR17","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","volume":"69","author":"DA Siegel","year":"2020","unstructured":"Siegel DA, O\u2019Neil ME, Richards TB, Dowling NF, Weir HK (2020) Prostate cancer incidence and survival, by stage and race\/ethnicity \u2014 United States, 2001\u20132017. MMWR Morb Mortal Wkly Rep 69(41):1473\u20131480","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"4253_CR18","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1080\/0284186X.2016.1191667","volume":"55","author":"FB Thomsen","year":"2016","unstructured":"Thomsen FB, Mikkelsen MK, Hansen RB, Krug AH, Glenth\u00f8j A, Stattin P et al (2016) Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center. Acta Oncol (Madr) 55(12):1456\u20131460","journal-title":"Acta Oncol (Madr)"},{"issue":"5","key":"4253_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/bju.13488","volume":"118","author":"DE Spratt","year":"2016","unstructured":"Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS et al (2016) Independent surgical validation of the new prostate cancer grade-grouping system. BJU Int 118(5):763\u2013769","journal-title":"BJU Int"},{"issue":"2","key":"4253_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/pcan.2016.66","volume":"20","author":"R Mathieu","year":"2017","unstructured":"Mathieu R, Moschini M, Beyer B, Gust KM, Seisen T, Briganti A et al (2017) Prognostic value of the new grade groups in prostate cancer: a multi-institutional European validation study. Prostate Cancer Prostatic Dis 20(2):197\u2013202","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"4253_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s00345-013-1184-2","volume":"32","author":"F O\u2019Kelly","year":"2014","unstructured":"O\u2019Kelly F, Elamin S, Cahill A, Aherne P, White J, Buckley J et al (2014) Characteristics of modern Gleason 9\/10 prostate adenocarcinoma: a single tertiary centre experience within the Republic of Ireland. World J Urol 32(4):1067\u20131074","journal-title":"World J Urol"},{"issue":"1","key":"4253_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.juro.2015.01.078","volume":"194","author":"CK Tsao","year":"2015","unstructured":"Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J et al (2015) Patients with biopsy Gleason 9 and 10 prostate cancer have significantly worse outcomes compared to patients with Gleason 8 disease. J Urol 194(1):91\u201397. https:\/\/doi.org\/10.1016\/j.juro.2015.01.078","journal-title":"J Urol"},{"issue":"7","key":"4253_CR23","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/his.14658","volume":"80","author":"LL Rijstenberg","year":"2022","unstructured":"Rijstenberg LL, Hansum T, Kweldam CF, K\u00fcmmerlin IP, Remmers S, Roobol MJ et al (2022) Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies. Histopathology 80(7):1041\u20131049","journal-title":"Histopathology"},{"issue":"5","key":"4253_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.5858\/arpa.2012-0128-OA","volume":"137","author":"ON Kryvenko","year":"2013","unstructured":"Kryvenko ON, Gupta NS, Virani N, Schultz D, Gomez J, Amin A et al (2013) Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: analysis of 184 radical prostatectomy specimens. Arch Pathol Lab Med 137(5):610\u2013617","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"4253_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.juro.2016.01.120","volume":"196","author":"AI Cole","year":"2016","unstructured":"Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA et al (2016) Prognostic value of percent Gleason grade 4 at prostate biopsy in predicting prostatectomy pathology and recurrence. J Urol 196(2):405\u2013411. https:\/\/doi.org\/10.1016\/j.juro.2016.01.120","journal-title":"J Urol"},{"key":"4253_CR26","doi-asserted-by":"publisher","unstructured":"Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, Van Der Kwast TH, Van Leenders GJLH (2015) Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol 28(3):457\u201364. Available from: https:\/\/doi.org\/10.1038\/modpathol.2014.116","DOI":"10.1038\/modpathol.2014.116"},{"issue":"4","key":"4253_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.eururo.2015.10.029","volume":"69","author":"G Sauter","year":"2016","unstructured":"Sauter G, Steurer S, Clauditz TS, Krech T, Wittmer C, Lutz F et al (2016) Clinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol 69(4):592\u2013598","journal-title":"Eur Urol"},{"key":"4253_CR28","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1097\/PAS.0000000000000691","volume":"40","author":"B Choy","year":"2016","unstructured":"Choy B, Pearce SM, Anderson BB, Shalhav AL, Zagaja G, Eggener SE et al (2016) Re: prognostic significance of percentage and architectural types of contemporary Gleason pattern 4 prostate cancer in radical prostatectomy. Am J Surg Pathol 40:1400\u20131406","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"4253_CR29","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1007\/s00345-022-04202-0","volume":"40","author":"A Martini","year":"2022","unstructured":"Martini A, Touzani A, Beauval J-B, Ruffion A, Olivier J, Gasmi A et al (2022) Heterogeneity of contemporary grade group 4 prostate cancer in radical prostatectomy specimens. World J Urol 40(12):2931\u20132937","journal-title":"World J Urol"},{"key":"4253_CR30","doi-asserted-by":"crossref","unstructured":"Nguyen JK, Li J, Ding C-KC, Weight CJ, Mckenney JK (2025) Correlation of large cribriform carcinoma and \u201cunfavorable histology\u201d with other Gleason pattern 4 subtypes: a proof-of-principle study evaluating 485 radical prostatectomy specimens with proposal for the concept of \u201cborderline histology.\u201d Ann Diagn Pathol 75:152","DOI":"10.1016\/j.anndiagpath.2024.152427"},{"issue":"2","key":"4253_CR31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41391-024-00802-6","volume":"28","author":"LJ Kroon","year":"2025","unstructured":"Kroon LJ, Remmers S, Hollemans E, Bangma CH, Roobol MJ, van Leenders GJLH (2025) Does prostate cancer without cribriform pattern have metastatic potential? Prostate Cancer Prostatic Dis 28(2):342\u2013244","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"4253_CR32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.eururo.2017.04.034","volume":"72","author":"MLK Chua","year":"2017","unstructured":"Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V et al (2017) A Prostate Cancer \u201c Nimbosus \u201d: Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. Eur Urol 72(5):665\u2013674","journal-title":"Eur Urol"},{"issue":"7","key":"4253_CR33","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41379-019-0221-0","volume":"32","author":"EI Verhoef","year":"2019","unstructured":"Verhoef EI, van Cappellen WA, Slotman JA, Kremers GJ, Ewing-Graham PC, Houtsmuller AB et al (2019) Three-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patterns. Mod Pathol 32(7):1032\u20131041. https:\/\/doi.org\/10.1038\/s41379-019-0221-0","journal-title":"Mod Pathol"},{"issue":"3","key":"4253_CR34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/his.12976","volume":"69","author":"CF Kweldam","year":"2016","unstructured":"Kweldam CF, Nieboer D, Algaba F, Amin MB, Berney DM, Billis A et al (2016) Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology 69(3):441\u2013449","journal-title":"Histopathology"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04253-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04253-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04253-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:25:17Z","timestamp":1786785917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04253-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4253"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04253-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}